Sherlyana Surja, MD
Allergy & Immunology · Toledo, OHNPI 1972890028
Payments from drug & device makers
Across 592 payments — averaging $34.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$732
- Takeda Pharmaceuticals U.S.A., Inc.$729
- Sanofi$724
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$10,00048%
- Food & beverage$10,44351%
- Education$1861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 107 | $11,281 |
| AstraZeneca(2 entities) | 81 | $1,430 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,085 |
| CSL Behring | 34 | $732 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $729 |
| Sanofi | 36 | $724 |
| Optinose US, Inc. | 27 | $534 |
| Novartis | 30 | $490 |
| Alk-abello, Inc | 26 | $438 |
| Pfizer | 33 | $431 |
| Pharming Healthcare, Inc. | 17 | $310 |
| Amgen | 11 | $257 |
| Boehringer Ingelheim | 15 | $253 |
| Genentech USA, Inc. | 10 | $241 |
| Kaleo, Inc. | 14 | $198 |
| Sunovion Pharmaceuticals Inc. | 22 | $197 |
| Teva Pharmaceuticals USA, Inc. | 9 | $184 |
| Grifols USA, LLC | 3 | $177 |
| AbbVie | 6 | $124 |
| Blueprint Medicines Corporation | 1 | $114 |
| Shire North American Group Inc | 5 | $95 |
| Biocryst US Sales Co., LLC | 3 | $83 |
| Actelion Pharmaceuticals US, Inc. | 2 | $68 |
| Octapharma USA, Inc. | 3 | $67 |
| Aimmune Therapeutics, Inc. | 3 | $67 |
| Lilly USA, LLC | 2 | $46 |
| USWM, LLC | 2 | $35 |
| Bio Products Laboratory USA, Inc. | 2 | $34 |
| Fresenius Kabi USA, LLC | 1 | $33 |
| LEO Pharma Inc. | 2 | $32 |
| Covis Pharma GmbH | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,630 in reported general payments places this provider in the 80th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 33 | $211,795 |
| Dupixent SyringeDupilumab | 18 | $86,704 |
| TezspireTezepelumab-Ekko | 14 | $63,181 |
| XolairOmalizumab | 15 | $49,037 |
| Dupixent PenDupilumab | 11 | $40,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $36,193 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,972 |
| DuleraMometasone/Formoterol | 24 | $9,173 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,239 |
| Epinephrine | 32 | $7,217 |
| XhanceFluticasone Propionate | 12 | $6,795 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,106 |
| Olopatadine Hcl | 35 | $3,371 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,228 |
| Azelastine Hcl | 81 | $1,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $732 | $211,79533 claims |
| AstraZenecaTezspire, Symbicort | $1,430 | $69,28837 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $11,281 | $44,43263 claims |
| Boehringer IngelheimSpiriva Respimat | $253 | $10,97221 claims |
| Optinose US, Inc.Xhance | $534 | $6,79512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Toledo
- Syed RehmanToledo$3.6M
- Adam UpdegraffToledo$379K
- Ghassan SafadiToledo$5K
- Sudhir RaoToledo$4K
- Sridhar GuduriDublin$11.3M
- Donald McNeilColumbus$4.8M
- Jonathan BernsteinCincinnati$4.5M
- David BernsteinCincinnati$2.7M
- Justin GreiweCincinnati$1M
- Sheharyar DurraniCincinnati$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.